8-K: Tonix Pharmaceuticals and Makana Therapeutics Collaborate on Xenotransplantation Research

Tonix Pharmaceuticals and Makana Therapeutics are partnering to study Tonix's TNX-1500 antibody in combination with Makana's human-compatible organs for treating organ failure.

Summary

• Tonix Pharmaceuticals and Makana Therapeutics have entered into a collaborative research agreement.
• The collaboration will focus on studying Tonix's anti-CD40L monoclonal antibody candidate, TNX-1500, with Makana's human-compatible organs and cells.
• The aim is to develop treatments for organ failure through xenotransplantation.
• The preclinical research and development collaboration may include Makana's kidney, heart, and islet cell transplant programs.
• The goal is to support the submission of an investigational new drug application (IND) to the FDA for compassionate use in xenotransplantation patients.
• Makana's genetically engineered pigs, which have deleted swine leukocyte antigen (SLA)2, have shown improved human compatibility.
• TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand.
• Tonix recently announced a contract with the U.S. DoDs Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200.

Sentiment

Score: 7

Explanation: The announcement is positive due to the collaboration between Tonix and Makana, which aims to advance xenotransplantation. However, the inherent risks and uncertainties associated with drug development and regulatory approvals temper the overall sentiment.

Positives

• The collaboration combines Tonix's TNX-1500 with Makana's genetically engineered organs, potentially leading to improved xenotransplantation outcomes.
• Makana's pigs have shown improved human compatibility, potentially increasing the success rate of xenotransplantation.
• TNX-1500 has demonstrated promising results in preventing rejection in animal studies.
• The collaboration aims to support an IND submission to the FDA, potentially accelerating the availability of xenotransplantation for compassionate use.
• Tonix recently announced a contract with the U.S. DoDs Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200.

Risks

• The success of the collaboration depends on the outcomes of preclinical studies and the subsequent FDA approval of an IND.
• Xenotransplantation faces challenges related to organ compatibility and immune rejection.
• The development of new pharmaceutical products involves significant risks related to clinical trials, regulatory approvals, and commercialization.
• Tonix's dependence on third parties for research and development efforts poses a risk.
• The company faces substantial competition in the biopharmaceutical industry.

Future Outlook

The collaboration aims to advance xenotransplantation as a viable treatment option for organ failure, with the goal of submitting an IND application to the FDA to support compassionate use.

Management Comments

• Seth Lederman, M.D., CEO of Tonix, stated that the agreement is a promising step towards utilizing xenotransplantation in the clinic.
• Joseph Tector, M.D., Ph.D., Founder of Makana, believes anti-CD40L is critical for successful xenotransplantation.
• Mark Platt, President and CEO of Makana, stated that the collaboration gives Makana the right product and partner to bring Makana toward clinical development.

Industry Context

Xenotransplantation is an emerging field with the potential to address the critical shortage of human organs for transplantation. This collaboration reflects a growing interest in combining novel immunomodulatory therapies with genetically engineered organs to improve transplant outcomes.

Comparison to Industry Standards

• Makana's development of the SLA DR knockout pig addresses a key challenge in xenotransplantation: antibody-mediated rejection.
• The company's focus on antigen discovery and deletion, rather than relying on inserted transgenes, aligns with efforts to simplify GE pig production and reduce therapy costs.
• The use of anti-CD40L monoclonal antibodies like TNX-1500 is a common strategy in xenotransplantation to prevent organ rejection, similar to approaches used by other companies in the field.
• The company's approach is differentiated by its focus on knockout-only pigs, which breed with greater efficiency and eliminate the challenge of retaining transgenic expression.

Stakeholder Impact

• Shareholders may benefit from the potential success of the collaboration and the development of new therapies.
• Employees of both Tonix and Makana may have opportunities to contribute to the research and development efforts.
• Patients with organ failure may benefit from the development of new xenotransplantation treatments.
• The collaboration may impact suppliers and partners of both companies.

Next Steps

• Conduct preclinical studies to evaluate the combination of TNX-1500 and Makana's genetically engineered organs.
• Submit an investigational new drug application (IND) to the FDA.
• Pursue clinical development of the combined therapy for xenotransplantation.

Key Dates

Keywords

xenotransplantation, TNX-1500, Makana Therapeutics, Tonix Pharmaceuticals, organ failure, anti-CD40L, monoclonal antibody, FDA, clinical trials, research collaboration